

11<sup>th</sup> February, 2022

To

BSE Limited  
Corporate Relationship Department  
P J Towers  
Dalal Street, Fort  
Mumbai – 400 001.

Dear Sir/Madam,

**Sub:** Outcome of Board Meeting held on 11<sup>th</sup> February, 2022

This is to inform you that the Board of Directors at their meeting held today, the 11<sup>th</sup> February, 2022 approved the Standalone Unaudited Financial results for the Quarter and nine months ended 31<sup>st</sup> December, 2021 along with the Limited Review Report of the Auditors, copy of which is enclosed for your records.

We hereby inform you that the Board Meeting commenced at 12.45 PM and concluded at 1.10 PM.

Thank You

With regards,

For **KMC SPECIALITY HOSPITALS (INDIA) LIMITED**



**Dr Manivannan**  
Managing Director  
DIN: 00910804



**Regd. Office :**  
**KMC Speciality Hospitals (India) Ltd.,**  
CIN - L85110TN1982PLC009781  
6, Royal Road, Cantonment, Trichy - 620 001.  
P 0431 - 4077777, F 0431 - 2415402  
E info@kauveryhospital.com | W www.kauveryhospital.com




## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF KMC SPECIALITY HOSPITALS (INDIA) LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **KMC SPECIALITY HOSPITALS (INDIA) LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)



**Ananthi Amarnath**  
Partner

Membership No. 209252  
UDIN:2209252ABIPQW7244

Date : February 11, 2022  
Place : Chennai



**KMC Speciality Hospitals (India) Limited**  
**Regd. Office: 6, Royal Road, Cantonment, Trichy - 620 001**  
**Corporate Identity Number: L85110TN1982PLC009781**

Unaudited financial results for the quarter and nine months ended December 31, 2021

(Rs. In Lakhs except EPS)

Particulars	Quarter ended			Nine months ended		Year ended
	December 31, 2021 (Unaudited)	September 30, 2021 (Unaudited)	December 31, 2020 (Unaudited)	December 31, 2021 (Unaudited)	December 31, 2020 (Unaudited)	March 31, 2021 (Audited)
<b>1 Income</b>						
a) Revenue from operations	3,836.08	3,282.30	2,897.80	10,347.16	7,270.37	10,263.72
b) Other income	54.25	44.37	36.97	144.03	113.53	192.64
<b>Total income</b>	<b>3,890.33</b>	<b>3,326.67</b>	<b>2,934.77</b>	<b>10,491.19</b>	<b>7,383.90</b>	<b>10,456.36</b>
<b>2 Expenses</b>						
a) Cost of materials consumed	81.73	54.69	76.77	194.11	194.18	268.43
b) Purchase of traded goods	465.38	417.19	381.77	1,355.23	964.28	1,345.79
c) Changes in inventory of traded goods	(5.02)	4.08	23.56	(7.86)	26.91	18.18
d) Employee benefits expense	696.20	671.09	596.32	1,998.53	1,654.71	2,151.11
e) Finance costs	14.97	10.31	21.76	38.03	66.31	95.22
f) Depreciation and amortisation expense	170.89	159.72	160.43	483.57	438.31	616.59
g) Other expenses	1,378.39	1,248.10	1,071.93	3,827.45	2,973.84	4,156.65
<b>Total expenses</b>	<b>2,802.54</b>	<b>2,565.18</b>	<b>2,332.54</b>	<b>7,889.06</b>	<b>6,318.54</b>	<b>8,651.97</b>
<b>3 Profit before tax (1-2)</b>	<b>1,087.79</b>	<b>761.49</b>	<b>602.23</b>	<b>2,602.13</b>	<b>1,065.36</b>	<b>1,804.39</b>
<b>4 Income tax expense</b>						
a) Current tax	266.99	217.82	180.15	691.26	340.57	566.48
b) Deferred tax	11.64	(20.14)	3.56	(35.46)	(24.33)	(40.04)
<b>Total income tax expense</b>	<b>278.63</b>	<b>197.68</b>	<b>183.71</b>	<b>655.80</b>	<b>316.24</b>	<b>526.44</b>
<b>5 Profit after tax (3-4)</b>	<b>809.16</b>	<b>563.81</b>	<b>418.52</b>	<b>1,946.33</b>	<b>749.12</b>	<b>1,277.95</b>
<b>6 Other comprehensive income</b>						
Items that will not be reclassified subsequently to profit or loss						
(a) Re-measurement of defined benefit plans	(15.10)	(26.08)	(5.16)	(45.32)	(11.81)	(15.58)
(b) Income tax effect	3.81	6.56	2.81	11.41	3.44	4.54
<b>Total other comprehensive income/(loss), net of tax</b>	<b>(11.29)</b>	<b>(19.52)</b>	<b>(2.35)</b>	<b>(33.91)</b>	<b>(8.37)</b>	<b>(11.04)</b>
<b>7 Total comprehensive income (5+6)</b>	<b>797.87</b>	<b>544.29</b>	<b>416.17</b>	<b>1,912.42</b>	<b>740.75</b>	<b>1,266.91</b>
<b>8 Paid-up equity share capital (Face value of Re. 1/- each)</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>	<b>1,630.85</b>
<b>9 Reserves i.e. Other equity</b>						<b>4,701.75</b>
<b>10 Earnings per share (EPS) of Re. 1/- each :</b>						
Basic and diluted EPS	0.50	0.35	0.25	1.19	0.45	0.78
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

**Notes:**

- These financial results have been prepared in accordance with Indian Accounting Standard ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016, as amended.
- The above unaudited financial results for the quarter and nine months ended December 31, 2021, in respect of KMC Speciality Hospitals (India) Limited ("the Company") have been reviewed by Audit Committee, approved and taken on record by the Board of Directors in their meeting held on February 11, 2022. The above results for quarter and nine months ended December 31, 2021 has also been subjected to limited review by the statutory auditors of the Company.
- The Company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under IND AS 108 - Operating Segment.
- The Company has opted to pay income taxes under the reduced tax regime as prescribed under Section 115BAA of the Income Tax Act, 1961 with effect from April 1, 2021. Accordingly, current tax liability for the quarter and nine months ended December 31, 2021 and quarter ended September 30, 2021 has been determined at the reduced rate, and accordingly recognized in the financial results.
- The Company has considered internal and certain external sources of information including credit reports, economic forecasts and industry reports up to the date of approval of the financial results in determining the impact on various elements of its financial results relating to COVID-19 pandemic. The Company has used the principles of prudence in applying judgments, estimates and assumptions including sensitivity analysis and based on the current estimates, the Company expects to fully recover the carrying amount of trade receivables, inventories, other financial assets and other current assets. The eventual outcome of impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results.
- The Company's operations for the period ended December 31, 2020 were impacted on account of outbreak of COVID-19 pandemic. The results for the period are therefore, not comparable with those of the previous periods.
- The Code on Wages 2019 and Code on Social Security 2020 "the Codes" relating to employee compensation and post-employment benefits received the Presidential Assent in September 2020 and the Code has been published in the Official Gazette. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period when the Code becomes effective.

Place: Chennai  
Date : February 11, 2022

Dr. S. Manivannan  
Managing Director  
DIN: 00910804

